Tsuneya Ikezu, MD, PhD

Ikezu photoProfessor, Departments of Pharmacology & Experimental Therapeutics and Neurology

Phone: 617-414-2658
Fax: 617-414-2649
Email: tikezu@bu.edu
Location: L-606 B
Background

Dr. Tsuneya Ikezu completed his undergraduate education at University of Tokyo School of Science and Arts, Japan. He earned his M. D. in 1991 and Ph.D. degrees from University of Tokyo School of Medicine in 1997. He joined the Boston University School of Medicine’s Department of Pharmacology and Experimental Therapeutics with a joint appointment in the Department of Neurology in 2010 as a Professor. Dr. Ikezu also leads the Laboratory of Molecular Neurotherapeutics. He joined the BU ADC in March 2011.

Research Interests
Dr. Ikezu’s research interests are focused on the role of neuroinflammation in the pathophysiology of dementia and as a potential therapeutic target of Alzheimer’s disease, HIV-associated dementia, and more recently chronic traumatic encephalopathy and encephalomyelopathy. He also studies enzymes that induce phosphorylation and aggregation of neurological disease-associated proteins, such as Alzheimer’s disease, HIV-associated dementia, and frontotemporal dementia.

ADC Role
Dr. Ikezu facilitates basic and translational research on neuroinflammation-related neurodegenerative disorders for BU ADC.

Awards/Memberships
Dr. Ikezu is a past recipient of the Vada Oldfield Alzheimer’s Research Award in 2000, the UNMC Distinguished Scientist Award in 2009, and the UNeMed Research Innovation Award in 2009. He serves on several editorial boards, including PLoS One.

Recent Publications
For a full list of publications please click here.

  • Takahashi H, Klein ZA, Bhagat SM, Kaufman AC, Kostylev MA, Ikezu T, Strittmatter SM. Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network. Acta Neuropathol. 2017 Jan 09. PMID: 28070672.
    View in: PubMed
  • Zhou Q, Yen A, Rymarczyk G, Asai H, Trengrove C, Aziz N, Kirber MT, Mostoslavsky G, Ikezu T, Wolozin B, Bolotina VM. Impairment of PARK14-dependent Ca(2+) signalling is a novel determinant of Parkinson’s disease. Nat Commun. 2016; 7:10332. PMID: 26755131.
    View in: PubMed
  • Stern RA, Tripodis Y, Baugh CM, Fritts NG, Martin BM, Chaisson C, Cantu RC, Joyce JA, Shah S, Ikezu T, Zhang J, Gercel-Taylor C, Taylor DD. Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy. J Alzheimers Dis. 2016; 51(4):1099-109. PMID: 26890775.
    View in: PubMed
  • Sapkota K, Mao Z, Synowicki P, Lieber D, Liu M, Ikezu T, Gautam V, Monaghan DT. GluN2D N-Methyl-d-Aspartate Receptor Subunit Contribution to the Stimulation of Brain Activity and Gamma Oscillations by Ketamine: Implications for Schizophrenia. J Pharmacol Exp Ther. 2016 Mar; 356(3):702-11. PMID: 26675679.
    View in: PubMed
  • Wolozin B, Ikezu T. Syk and Yea Shall Find. EBioMedicine. 2015 Nov; 2(11):1590-1. PMID: 26870779.
    View in: PubMed
  • Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, Wolozin B, Butovsky O, Kügler S, Ikezu T. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015 Nov; 18(11):1584-93. PMID: 26436904.
    View in: PubMed
  • Varnum MM, Kiyota T, Ingraham KL, Ikezu S, Ikezu T. The anti-inflammatory glycoprotein, CD200, restores neurogenesis and enhances amyloid phagocytosis in a mouse model of Alzheimer’s disease. Neurobiol Aging. 2015 Nov; 36(11):2995-3007. PMID: 26315370.
    View in: PubMed
  • Woodbury ME, Freilich RW, Cheng CJ, Asai H, Ikezu S, Boucher JD, Slack F, Ikezu T. miR-155 Is Essential for Inflammation-Induced Hippocampal Neurogenic Dysfunction. J Neurosci. 2015 Jul 1; 35(26):9764-81. PMID: 26134658.
    View in: PubMed